The Medicare Rights Center reports that President Trump’s executive order on prescription drug pricing supports key drug ...

Fetterman appealed to President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. personally.

CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for Wegovy and Zepbound ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

In a New York Times column this week, the Pennsylvania Democrat shared his experience taking Mounjaro while advocating for ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The Trump administration rejected a proposed rule to allow Medicare to cover blockbuster obesity drugs for weight loss alone ...